JP2016505617A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505617A5
JP2016505617A5 JP2015551659A JP2015551659A JP2016505617A5 JP 2016505617 A5 JP2016505617 A5 JP 2016505617A5 JP 2015551659 A JP2015551659 A JP 2015551659A JP 2015551659 A JP2015551659 A JP 2015551659A JP 2016505617 A5 JP2016505617 A5 JP 2016505617A5
Authority
JP
Japan
Prior art keywords
composition
compound
subject
itpr2
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015551659A
Other languages
English (en)
Japanese (ja)
Other versions
JP6242402B2 (ja
JP2016505617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2013/051508 external-priority patent/WO2014107124A1/en
Publication of JP2016505617A publication Critical patent/JP2016505617A/ja
Publication of JP2016505617A5 publication Critical patent/JP2016505617A5/ja
Application granted granted Critical
Publication of JP6242402B2 publication Critical patent/JP6242402B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015551659A 2013-01-03 2013-12-13 多汗症の治療 Active JP6242402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361748592P 2013-01-03 2013-01-03
US61/748,592 2013-01-03
PCT/SE2013/051508 WO2014107124A1 (en) 2013-01-03 2013-12-13 Treatment of hyperhidrosis

Publications (3)

Publication Number Publication Date
JP2016505617A JP2016505617A (ja) 2016-02-25
JP2016505617A5 true JP2016505617A5 (enExample) 2016-09-15
JP6242402B2 JP6242402B2 (ja) 2017-12-06

Family

ID=51062371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015551659A Active JP6242402B2 (ja) 2013-01-03 2013-12-13 多汗症の治療

Country Status (6)

Country Link
US (2) US9809820B2 (enExample)
EP (1) EP2958572B1 (enExample)
JP (1) JP6242402B2 (enExample)
CN (1) CN105025903B (enExample)
CA (1) CA2896939C (enExample)
WO (1) WO2014107124A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809820B2 (en) * 2013-01-03 2017-11-07 Hidros Therapeutics International Ab Treatment of hyperhidrosis
MX367563B (es) 2015-03-20 2019-08-27 Unilever Nv Composición antitranspirante.
CN110643598A (zh) * 2018-06-26 2020-01-03 煌鼎科技有限公司 促进皮肤凹疤愈合及毛孔收缩的酵母dna原料制法
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019055D0 (en) * 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
DK1606406T4 (da) * 2003-03-21 2013-12-16 Santaris Pharma As Short Interfering RNA (siRNA) Analogues
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
AU2008314628B2 (en) 2007-10-18 2014-03-06 Rose U Topical glycopyrrolate formulations
CA2745376A1 (en) 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
CN102573875A (zh) 2009-08-14 2012-07-11 阿勒根公司 使用速激肽再靶向内肽酶治疗癌症的方法
WO2012112422A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
US9809820B2 (en) * 2013-01-03 2017-11-07 Hidros Therapeutics International Ab Treatment of hyperhidrosis

Similar Documents

Publication Publication Date Title
AU2019210578B2 (en) C/EBP alpha saRNA compositions and methods of use
Lee et al. A Glu-urea-Lys ligand-conjugated lipid nanoparticle/siRNA system inhibits androgen receptor expression in vivo
US11965163B2 (en) HNF4a saRNA compositions and methods of use
US10081598B2 (en) Cationic lipid
TR201908314T4 (tr) Glutatyon bazlı ilaç dağıtım sistemi.
WO2012170957A3 (en) Retinoid-liposomes for enhancing modulation of hsp47 expression
JP2011516094A5 (enExample)
NZ718817A (en) Lipid formulations for delivery of messenger rna
JP2018504896A (ja) 分子の細胞内送達のためのペプチドおよびナノ粒子
JP2016505617A5 (enExample)
CN108779463A (zh) 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘
JP6242402B2 (ja) 多汗症の治療
JP2013542196A5 (enExample)
US11149271B2 (en) Method and pharmaceutical composition for treating cancer
CN113316459A (zh) 包含皮肤穿透核酸复合物作为有效成分的用于预防或治疗特应性皮炎的组合物
WO2019197845A1 (en) Sirt1-sarna compositions and methods of use
WO2020208361A1 (en) Sirt1-sarna compositions and methods of use
AU2018101287A4 (en) Method and pharmaceutical composition for treating cancer
CA2980975C (en) C/ebp alpha sarna compositions and methods of use
Levi Molecular medicine: Promises and patience
CN104174031A (zh) 逆转肿瘤多药耐药的基因组合物-h-R3/PAMAM G5/GCS siRNA及其应用
Gayral et al. Modulating MicroRNA Expression for the Therapy of Pancreatic Cancer
HK40052629A (en) Composition for preventing or treating atopic dermatitis comprising skin penetrating nucleic acid complex as an active ingredient
NZ758283A (en) Lipid formulations for delivery of messenger rna
WO2011117685A3 (es) Peptidos anticonceptivos derivados del veneno de la araña